trending Market Intelligence /marketintelligence/en/news-insights/trending/6YNtygJhZlVHsnvJ4BySxA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Neoleukin Therapeutics raises $86.2M via stock offering

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Neoleukin Therapeutics raises $86.2M via stock offering

Neoleukin Therapeutics Inc. raised about $86.2 million in gross proceeds from a common stock offering after underwriters fully exercised their option to purchase additional shares.

The Seattle-based biotechnology company sold 10,263,750 shares for $8.40 each, including the 1,338,750 additional shares purchased by underwriters.

Neoleukin Therapeutics, which develops immunotherapies for cancer, inflammation and autoimmunity, plans to use the net proceeds to primarily advance the clinical development of the company's experimental treatment NL-201.

The company will also use the proceeds to develop its preclinical pipeline and to fund working capital and for general corporate purposes, including capital improvements to properties it leases.

BofA Securities, Piper Jaffray and Guggenheim Securities were the joint book-running managers of the offering, with Canaccord Genuity serving as lead manager.